Xavier Durando

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Topics

Locally Advanced

Endometrial Cancer

Tyrosine Kinase

Top Venues

Breast cancer research and treatment

International journal of environmental research and public health

OncoTargets and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Julien Guerin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, Simon Thezenas, Emmanuel Desandes, Marie-Cécile Le Deley, Xavier Durando, Anne Jaffré, Ikram Es-Saad, Hugo Crochet, Marie Le Morvan, François Lion, Judith Raimbourg, Oussama Khay, Franck Craynest, Alexia Giro, Yec'han Laizet, Aurélie Bertaut, Frederik Joly, Alain Livartowski, Pierre Etienne Heudel
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International journal of environmental research and public health 21 (2) (2024)
Julien Guerin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, Simon Thezenas, Emmanuel Desandes, Marie-Cécile Le Deley, Xavier Durando, Anne Jaffré, Ikram Es-Saad, Hugo Crochet, Marie Le Morvan, François Lion, Judith Raimbourg, Oussama Khay, Franck Craynest, Alexia Giro, Yec'han Laizet, Aurélie Bertaut, Frederik Joly, Alain Livartowski, Pierre Etienne Heudel
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International journal of environmental research and public health 21 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Julien Guerin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, Simon Thezenas, Emmanuel Desandes, Marie-Cécile Le Deley, Xavier Durando, Anne Jaffré, Ikram Es-Saad, Hugo Crochet, Marie Le Morvan, François Lion, Judith Raimbourg, Oussama Khay, Franck Craynest, Alexia Giro, Yec'han Laizet, Aurélie Bertaut, Frederik Joly, Alain Livartowski, Pierre Etienne Heudel
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International journal of environmental research and public health 21 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
François Ducray, Carole Ramirez, Marie Robert, Florent Marguet, Charlotte Bronnimann, Olivier Chinot, Florian Estrade, Xavier Durando, Stéphanie Cartalat, Jeremy Bastid, Hugues Bienayme, Caroline Lemarchand
A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules. Pharmaceutics 15 (12) (2023)
Nathan El-Ghazzi, Xavier Durando, Alexia Giro, Tressie Herrmann
Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab. OncoTargets and therapy 16 (2023)
Angeline Ginzac, Marie-Céleste Ferreira, Anne Cayre, Clément Bouvet, Julian Biau, Ioana Molnar, Nicolas Saroul, Nathalie Pham-Dang, Xavier Durando, Maureen Bernadach
Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): a study protocol for a prospective, multicentre trial. BMC cancer 23 (1) (2023)
François Ducray, Carole Ramirez, Marie Robert, Florent Marguet, Charlotte Bronnimann, Olivier Chinot, Florian Estrade, Xavier Durando, Stéphanie Cartalat, Jeremy Bastid, Hugues Bienayme, Caroline Lemarchand
A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules. Pharmaceutics 15 (12) (2023)
Brice Leyrat, Xavier Durando, Céleste Pinard, Maureen Bernadach
Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report. OncoTargets and therapy 14 (2021)
Angeline Ginzac, Guillaume Dupic, Lucie Brun, Ioana Molnar, Mélanie Casile, Xavier Durando, Pierre Verrelle, Jean-Jacques Lemaire, Toufic Khalil, Julian Biau
Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial. BMC cancer 21 (1) (2021)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)